Hepatic contrast enhancement at CT: influence of intravenous glucagon in a canine model

Radiology. 1995 Nov;197(2):365-8. doi: 10.1148/radiology.197.2.7480678.

Abstract

Purpose: To investigate the effect of glucagon on the timing and degree of hepatic enhancement at computed tomography.

Materials and methods: Each of 11 dogs underwent injection of contrast material at two uniphasic rates (0.5 mL/sec and 1.5 mL/sec) with without previous intravenous administration of 0.5 mg of glucagon. Scans were obtained at a single intrahepatic level every 3.5 seconds for 120-160 seconds. Attenuation values in the liver, aorta, portal vein, and inferior vena cava (IVC) were measured.

Results: Glucagon administration was associated with greater hepatic enhancement throughout the study: Peak hepatic enhancement was greater at contrast injection rates of 0.5 mL/sec (P = .021) and 1.5 mL/sec (P = .0001). Peak hepatic enhancement also occurred earlier during the glucagon runs. Portal vein enhancement was greater during the glucagon runs at an injection rate of 1.5 mL/sec (P = .032). IVC enhancement was greater during the nonglucagon runs at 0.5 mL/sec (P = .013) and at 1.5 mL/sec (P = .005).

Conclusion: Intravenous administration of glucagon before contrast material injection produces greater and more rapid hepatic enhancement in a canine model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aortography
  • Blood Pressure
  • Contrast Media / administration & dosage
  • Dogs
  • Female
  • Glucagon* / administration & dosage
  • Heart Rate
  • Injections, Intravenous
  • Liver / blood supply
  • Liver / diagnostic imaging*
  • Male
  • Pilot Projects
  • Portal Vein / physiology
  • Portography
  • Pulse
  • Radiographic Image Enhancement / methods*
  • Regional Blood Flow
  • Time Factors
  • Tomography, X-Ray Computed / methods*
  • Vena Cava, Inferior / diagnostic imaging

Substances

  • Contrast Media
  • Glucagon